TLIS Talis Biomedical Corporation: Forward P/S Multiple

Talis Biomedical revenues are based on rapid tests and the implementation of the Talis One system for clinics. The projected P/S metric visualizes market confidence in these sales, where 26.60 determines the current status of the parameter. Efficiency is supported by contract electronics manufacturing and third-party logistics. Independence from macroeconomic trends and the demand for innovation transform the company into a resilient defensive asset.

Talis Biomedical Corporation - TLIS Market Cap to Expected Sales Ratio (period 07/04/2022 - 09/07/2024)

Metric breakdowns and analytics for talis.bio (TLIS)

- current price and projected stock value:

Stock Price Talis Biomedical Corporation|TLIS - Average Forecast Price

- company stock capitalization data:

Market Capitalization Talis Biomedical Corporation|TLIS - Business Value

- issuer book value statistics:

Book Value per Share Talis Biomedical|TLIS - Book Valuation of Business|Market Capitalization to Book Value Ratio talis.bio|TLIS - Cumulative Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

TLIS - Annual Net Income|Future Profit Talis Biomedical|TLIS - P/E Multiple|Forward P/E Multiple Talis Biomedical Corporation|TLIS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Talis Biomedical Corporation|TLIS - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months Talis Biomedical|TLIS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth talis.bio|TLIS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Talis Biomedical

- sales volume and revenue indicators:

TLIS - Company Sales Volume|Company Future Sales Volume Talis Biomedical Corporation|TLIS - Market Cap to Sales Volume|Forward Price-to-Revenue Multiple Talis Biomedical Corporation

Summary company analytics:Talis Biomedical Corp (TLIS)

Product sample of Talis Biomedical Corporation

Talis Biomedical (TLIS) possesses high R&D potential in the development of the Talis One cloud platform, positioning the company as a technological innovator in the rapid diagnostics sector. An analysis of the forward P/S ratio allows for an assessment of the company's market value relative to expected revenue, where a compression of this multiple signals a shift in the macroeconomic cycle and the correlation of shares with other assets, helping investors rebalance capital in a timely manner.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Inc (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple Semler (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network, Inc. BFLY|mesalabs.com - Price-to-Projected Revenue Ratio|QSI: Forward Price-to-Revenue Multiple|Forward Price to Sales NNOX (Nano-X Imaging)|QTRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio 908 Devices Corporation (MASS)|Price-to-Projected Revenue Ratio CapsoVision, Inc.|MXCT - Projected Price to Revenue|Forward Price-to-Revenue Multiple RPID (Rapid Micro Biosystems)|Forward P/S Multiple Seer Inc (SEER)|Forward P/S Multiple HYPR (Hyperfine Corp)|Market Cap to Expected Sales Ratio FONAR Corporation Inc (FONR)|DXR - Price-to-Projected Revenue Ratio|Future Price to Revenue MDAI|VivoSim Labs Inc (VIVS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Aclarion Inc|AKYA (Akoya Biosciences Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Cesca Therapeutics THMO|Price-to-Projected Revenue Ratio T2 Biosystems, Inc. (TTOO)